These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 23549409)

  • 1. Fecal excretion of Bifidobacterium infantis 35624 and changes in fecal microbiota after eight weeks of oral supplementation with encapsulated probiotic.
    Charbonneau D; Gibb RD; Quigley EM
    Gut Microbes; 2013; 4(3):201-11. PubMed ID: 23549409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial.
    Ki Cha B; Mun Jung S; Hwan Choi C; Song ID; Woong Lee H; Joon Kim H; Hyuk J; Kyung Chang S; Kim K; Chung WS; Seo JG
    J Clin Gastroenterol; 2012 Mar; 46(3):220-7. PubMed ID: 22157240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome.
    Whorwell PJ; Altringer L; Morel J; Bond Y; Charbonneau D; O'Mahony L; Kiely B; Shanahan F; Quigley EM
    Am J Gastroenterol; 2006 Jul; 101(7):1581-90. PubMed ID: 16863564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Bifidobacterium infantis 35624 in patients with irritable bowel syndrome: a meta-analysis.
    Yuan F; Ni H; Asche CV; Kim M; Walayat S; Ren J
    Curr Med Res Opin; 2017 Jul; 33(7):1191-1197. PubMed ID: 28166427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Probiotic Bifidobacterium longum NCC3001 Reduces Depression Scores and Alters Brain Activity: A Pilot Study in Patients With Irritable Bowel Syndrome.
    Pinto-Sanchez MI; Hall GB; Ghajar K; Nardelli A; Bolino C; Lau JT; Martin FP; Cominetti O; Welsh C; Rieder A; Traynor J; Gregory C; De Palma G; Pigrau M; Ford AC; Macri J; Berger B; Bergonzelli G; Surette MG; Collins SM; Moayyedi P; Bercik P
    Gastroenterology; 2017 Aug; 153(2):448-459.e8. PubMed ID: 28483500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles.
    O'Mahony L; McCarthy J; Kelly P; Hurley G; Luo F; Chen K; O'Sullivan GC; Kiely B; Collins JK; Shanahan F; Quigley EM
    Gastroenterology; 2005 Mar; 128(3):541-51. PubMed ID: 15765388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early Probiotic Supplementation of Healthy Term Infants with
    Hiraku A; Nakata S; Murata M; Xu C; Mutoh N; Arai S; Odamaki T; Iwabuchi N; Tanaka M; Tsuno T; Nakamura M
    Nutrients; 2023 Mar; 15(6):. PubMed ID: 36986131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of multispecies probiotics on irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial.
    Yoon JS; Sohn W; Lee OY; Lee SP; Lee KN; Jun DW; Lee HL; Yoon BC; Choi HS; Chung WS; Seo JG
    J Gastroenterol Hepatol; 2014 Jan; 29(1):52-9. PubMed ID: 23829297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and Microbiological Effect of a Multispecies Probiotic Supplementation in Celiac Patients With Persistent IBS-type Symptoms: A Randomized, Double-Blind, Placebo-controlled, Multicenter Trial.
    Francavilla R; Piccolo M; Francavilla A; Polimeno L; Semeraro F; Cristofori F; Castellaneta S; Barone M; Indrio F; Gobbetti M; De Angelis M
    J Clin Gastroenterol; 2019 Mar; 53(3):e117-e125. PubMed ID: 29688915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of synbiotic fermented milk containing Lactobacillus acidophilus La-5 and Bifidobacterium animalis ssp. lactis BB-12 on the fecal microbiota of adults with irritable bowel syndrome: A randomized double-blind, placebo-controlled trial.
    Bogovič Matijašić B; Obermajer T; Lipoglavšek L; Sernel T; Locatelli I; Kos M; Šmid A; Rogelj I
    J Dairy Sci; 2016 Jul; 99(7):5008-5021. PubMed ID: 27157575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acacia fiber or probiotic supplements to relieve gastrointestinal complaints in patients with constipation-predominant IBS: a 4-week randomized double-blinded placebo-controlled intervention trial.
    JanssenDuijghuijsen L; van den Belt M; Rijnaarts I; Vos P; Guillemet D; Witteman B; de Wit N
    Eur J Nutr; 2024 Aug; 63(5):1983-1994. PubMed ID: 38653808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of
    Lewis ED; Antony JM; Crowley DC; Piano A; Bhardwaj R; Tompkins TA; Evans M
    Nutrients; 2020 Apr; 12(4):. PubMed ID: 32326347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Probiotic bacteria Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07 versus placebo for the symptoms of bloating in patients with functional bowel disorders: a double-blind study.
    Ringel-Kulka T; Palsson OS; Maier D; Carroll I; Galanko JA; Leyer G; Ringel Y
    J Clin Gastroenterol; 2011 Jul; 45(6):518-25. PubMed ID: 21436726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of a multispecies probiotic supplement on quantity of irritable bowel syndrome-related intestinal microbial phylotypes.
    Lyra A; Krogius-Kurikka L; Nikkilä J; Malinen E; Kajander K; Kurikka K; Korpela R; Palva A
    BMC Gastroenterol; 2010 Sep; 10():110. PubMed ID: 20849659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Effectiveness and Safety of Multi-Strain Probiotic Preparation in Patients with Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized Controlled Study.
    Skrzydło-Radomańska B; Prozorow-Król B; Cichoż-Lach H; Majsiak E; Bierła JB; Kanarek E; Sowińska A; Cukrowska B
    Nutrients; 2021 Feb; 13(3):. PubMed ID: 33652763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A double blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome.
    Drouault-Holowacz S; Bieuvelet S; Burckel A; Cazaubiel M; Dray X; Marteau P
    Gastroenterol Clin Biol; 2008 Feb; 32(2):147-52. PubMed ID: 18387426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bifidobacterium infantis 35624 modulates host inflammatory processes beyond the gut.
    Groeger D; O'Mahony L; Murphy EF; Bourke JF; Dinan TG; Kiely B; Shanahan F; Quigley EM
    Gut Microbes; 2013; 4(4):325-39. PubMed ID: 23842110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of Clostridium butyricum on symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial.
    Sun YY; Li M; Li YY; Li LX; Zhai WZ; Wang P; Yang XX; Gu X; Song LJ; Li Z; Zuo XL; Li YQ
    Sci Rep; 2018 Feb; 8(1):2964. PubMed ID: 29445178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bifidobacterium infantis 35624: a novel probiotic for the treatment of irritable bowel syndrome.
    Brenner DM; Chey WD
    Rev Gastroenterol Disord; 2009; 9(1):7-15. PubMed ID: 19367213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy of Bifidobacterium quadruple viable tablet in the treatment of diarrhea predominant irritable bowel syndrome: protocol for a randomized, double-blind, placebo-controlled, multicenter trial.
    Bai T; Zeng H; Long Y; Li X; Sun X; Lan Y; Gao L; Zhang L; Feng Z; Hou X
    Trials; 2020 Jun; 21(1):597. PubMed ID: 32605578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.